Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Statistics
February 2, 2009
- R&D NEWS IN BRIEF
February 2, 2009
- ARB + Diuretic Combinations from Takeda, Novartis Approved at the Same Time
February 2, 2009
- JGA to Make Proposals to Improve Environment for Use of Generics
February 2, 2009
- NEW PRODUCTS
February 2, 2009
- Industry Should Make Concerted Efforts to Make Generics More Reliable: Mr Kinoshita
February 2, 2009
- Pfizer to Acquire Wyeth
February 2, 2009
- Oncolys, Sysmex to Jointly Develop Diagnostic Agents for Cancer
February 2, 2009
- Industry Concerned about Obama Administration's Intervention in Drug Pricing
February 2, 2009
- FUJIFILM to Market Given Imaging's PillCam SB Endoscope
February 2, 2009
- Astellas Proposes Acquisition to CV Therapeutics
February 2, 2009
- JIRA to Demand Digital X-Ray Imaging Fee
February 2, 2009
- Financial Crisis Offers Opportunity for Cash-Rich Biopharma Companies: BCG
February 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 2, 2009
- Hisamitsu to Comarket Fosamac with Banyu
February 2, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 2, 2009
- Wholesalers Have Been Driven Over the Edge: Mr Kimura
February 2, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2009
- Cravit to See NHI Price Listing for 41 Generics from 32 Companies
January 26, 2009
- Endometrial Ablation Using Microwaves Approved as Advanced Therapy
January 26, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…